Case Report
A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab
Table 2
The clinical course before and after omalizumab treatment.
| Omalizumab dose pack (months) | Before treatment | Post 2 months (5~8 W)
| Post 4 months (13~16 W)
| Post 6 months (21~24 W)
| After 1 year
|
| IgE (IU/mL) | 97.4 | 181 | 159 | 144 | 102 | PEF (L/sec): morning/evening | 210/290 | 280/330 | 280/310 | 220/280 | 230/320 | PSL dose (mg/day) | 15 | 10 | 10 | 10/5 | 15 | Rescue frequency (times/28 day) | 12 | 0 | 0 | 7 | 10 | Daily life (days/28 days) | | | | | | No difficulty | 0 | 5 | 28 | 16 | 4 | Slight difficulty | 19 | 23 | | 7 | 24 | Extreme difficulty | 9 | | | 5 | | Deep sleep (days/28 days) | 20 | 28 | 28 | 24 | 28 | Cough Mild | 15 | 14 | 8 | 7 | 9 | (days/28 days) strong | 3 | 0 | 1 | 5 | 0 | none | 9 | 14 | 19 | 16 | 16 | No symptom days (days/28 days) | 20 | 28 | 27 | 21 | 25 | Lung function: FEV1 (L) | 1.93 | | 2.34 | | | % FEV1 (% ) | 63.9 | | 76.4 | | | PEF (L/sec) | 4.89 | | 5.84 | | |
|
|